This site is intended for health professionals only
Monday 11 December 2017
Share |

Topic: *** Editor's Pick

November 30, 2017
Ann Page and Mark Borthwick will be co-Chairs of UKCPA for two years

At the UKCPA Conference on Saturday 25 November it was announced that Ann Page and Mark Borthwick will be co-Chairs of UKCPA for two years from 1 January 2018.

Mr Borthwick held the post of Chair from 2013 to 2015 and was supported by Ms Page as Vice-Chair during this time. Since May 2015 Ms Page has led the association as Chair, and Mr Borthwick has continued his involvement in the strategic direction of UKCPA as Immediate Past Chair.

November 30, 2017
At their annual Conference on 25 November 2017 the UKCPA celebrated two outstanding leaders in pharmacy

Mr Philip Howard, Consultant Pharmacist in Antimicrobials at Leeds Teaching Hospitals NHS Trust, was given the UKCPA Lifetime Achievement Award for 2017.

November 30, 2017
Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use

Novartis has announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase III STRIVE study evaluating erenumab in the prevention of episodic migraine (defined in STRIVE as 4 to 14 migraine days per month).1


November 27, 2017
Survey highlights need for improved education and standardised referral pathways for oncofertility

Results of a new survey highlight the need for improved education and standardised guidance for oncologists initiating cancer treatment in women who may want to safeguard their fertility.1


November 17, 2017
Robust analytical, pharmacological, non–clinical and clinical data demonstrated the similarity of Cyltezo® to Humira®

Boehringer Ingelheim has announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases in adults and children.

November 17, 2017
Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe

GlaxoSmithKline and Innoviva, Inc have announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

November 17, 2017
First pilot of a new cancer care model which leverages the role of the pharmacist by the Vanguard New Models of Care Programme

Novartis has announced the launch of The Royal Marsden Partners Cancer Vanguard (RMP) Oncology Pharmacy Service Improvement Joint Working Project.


Cancer patients living in North West and South West London will now benefit from the Joint Working Project which will aim to improve the quality of cancer patient care. The project, run by Novartis and the Royal Marsden, will run for up to two years as a pilot with the potential to be expanded across other NHS sites.

November 16, 2017
Ribociclib in combination with an aromatase inhibitor is a new and effective treatment option for women in England and Wales with the most common form of advanced breast cancer

Kisqali® (ribociclib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer.


November 16, 2017
Adult-onset Still’s disease and systemic juvenile idiopathic arthritis are rare systemic disorders of auto-inflammatory nature

Swedish Orphan Biovitrum AB has announced that the first patient has been randomised in the Phase III study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatment of Still’s disease.


November 15, 2017
Kavya Gopal from Sandoz to take-up chair role of Association

The British Biosimilars Association (BBA), the representative group of biosimilar manufacturers in the UK, has announced that Kavya Gopal will become its new chair with immediate effect.


Kavya, who is currently Head of the Specialty Business for Sandoz UK, has nearly 20 years of experience in the pharmaceutical industry leading successful teams in the US and in Global roles for Novartis/Sandoz before moving to the UK earlier this year. 


November 15, 2017
Fulvestrant in combination with palbociclib showed progression-free survival improvement of 4.9 months compared to combination of fulvestrant with placebo

AstraZeneca has announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.1


November 15, 2017
For patients undergoing an allogeneic haematopoietic stem cell transplant, complications arising from cytomegalovirus infection can be life threatening

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of letermovir for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1


November 14, 2017
All Multi-Purpose Blisters are tamper-evident, moisture resistant and ultraviolet inhibitant

With over 45 years’ experience in the field, Medi-Dose has been recognised as the leader in solid oral unit dose packaging.


With the company’s new versatile Multi-Purpose Blisters, you can easily package, label and secure even more sizes and types of meds.  Large medication, compounded and USP <800> drugs, double and triple “0” capsules, unit of use packaging, repacked meds and suppositories are just a few of the medication forms that can be accommodated with the new MPB. 


November 10, 2017
ABP 215 is being developed as a biosimilar to bevacizumab

Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorisation of ABP 215, a biosimilar to Avastin® (bevacizumab).


November 10, 2017
If licensed, ocrelizumab will be an important new treatment option for adults with active relapsing forms of multiple sclerosis, approved on the basis of superior efficacy on three major markers of disease activity and disability progression compared to comparative control groups

Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of ocrelizumab for adults with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for adults with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.


November 10, 2017
Positive opinion based on five studies demonstrating Nplate reduces rates of bleeding in children with rare blood disorder

Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (for example,corticosteroids, immunoglobulins).


November 9, 2017
48-week Phase III data showed Cyltezo® and Humira® have similar efficacy, safety and immunogenicity in people with rheumatoid arthritis

Boehringer Ingelheim has announced one-year data from Voltaire®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®.


November 9, 2017
Ustekinumab showed significant improvements in various disease measures compared with placebo, including musculoskeletal, mucocutaneous, immunological markers and flares

Janssen has announced positive results from a randomised, placebo-controlled Phase II study investigating the anti-interleukin (IL)-12/23 monoclonal antibody Stelara® (ustekinumab) in the treatment of active systemic lupus erythematosus (SLE or lupus).


November 9, 2017
NICE also recommends use of Merck’s multiple sclerosis therapy cladribine (Mavenclad®) for highly active disease in adults

NHS England has entered into a commercial agreement that allows NHS patients in England immediate access to the innovative new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad®).1


NHS England and Merck, the manufacturer of cladribine tablets, have partnered on the commercial access agreement, representing an example of a “win-win-win” for the NHS, patients and industry at a time of intense financial pressure on the NHS.

November 9, 2017
Tolvaptan reduced the rate of decline of kidney function by 35% over a 12-month period, compared to placebo, in patients with autosomal dominant polycystic kidney disease

Otsuka has announced detailed results from the Phase III REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD).

November 9, 2017
The survey highlighted that medicines used by patients across Europe have integrated supply chains

EFPIA has published results of a survey underlining the sheer scale and importance of the medicines issues that must be addressed as part of the Brexit discussions in order to protect public health.


Commenting on the survey, EFPIA Director General, Nathalie Moll said. “The survey underlines the  scale of the task ahead. For life saving and life improving medicines, the EU and UK cannot afford to wait any longer to ensure that the necessary cooperation on medicines is in place from the day the UK leaves the EU.”

November 2, 2017
Patients with ‘forgotten cancer’ to access new immunotherapy Tecentriq® (atezolizumab) via Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has recommended the use of a new immunotherapy via the Cancer Drugs Fund.


November 2, 2017
CT-P13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients

Celltrion Healthcare and Pfizer have jointly announced data from the Phase III, randomised controlled, switching trial comparing CT-P13 and reference infliximab.


The data showed comparable efficacy and safety between all treatment groups (maintained and switched) in patients with moderate to severe Crohn’s disease (CD) up to one year.1


November 2, 2017
Late-breaking data demonstrate rapid improvement in patient-reported symptoms in patients intolerant or refractory to anti-TNF treatment

Janssen has presented new late-breaking data from UNITI-1 assessing Crohn's disease symptom improvement in patients during the first 2 weeks after an intravenous (IV) infusion dose of Stelara®(ustekinumab).1


The data presented at the 25th United European Gastroenterology Week (UEGW 2017) showed that patient-reported symptom improvement began as early as day 1 post ustekinumab IV infusion and was observed consistently at day 8 and beyond when compared with placebo.1


You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher